CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European UnionBOSTON, S…